Revenue grew 10.5%, while EBITDA surged 15.3% with improved margins. The company faces ongoing legal proceedings in the U.S. Sun Pharma Q3 Results: PAT advances 15% YoY to Rs 2,903 crore, beats ...

Copyright © 2025 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.

Going into Q2, the inflationary trends continued and we had another 6-7% hike. We expect this inflationary trend to continue well into Q3 as well. Going forward, we are taking very concrete steps to ...